Zoek in de HOVON website
Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.
Clinical picture: NHL (Non Hodgkin Lymphoma)
Trial:
News
1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms
News
HO137 news
09Jan2019: Participants are informed by email that start up of the trial will not be continued. (Financial support by the KWF was necessary but this was not granted.)
12Nov2017: Trial has been set on hold because Sandoz will not support the trial anymore.
07Jun2017: The trial will continue with Rixathon (rituximab biosimilar from Sandoz) instead of obinutuzumab. The new protocol is in development and participating sites are informed by email.
31Aug2016: Trial has been set on hold. Reason for this is that the GOYA study (obinutuzumab treatment for DLBCL) didn't reach its primary endpoint. Currently there are discussions with Roche about the continuation of the HO137. As soon as there is more information, participating sites will be informed.
1. Overview
Status
closed
Study details
Type of study
Prospective randomized Phase II study
Echelon level
Level D
Type of monitoring for this study
Site evaluation visits
Target number of patients
170
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.